|
|
|
|
Management
|
|
|
|
 |
|
CEO
Martin Bonde, Ph.D, B.Comm.
- Serial entrepreneur, founded and managed several companies in Denmark and the US (NatImmune A/S, Arpida A/S, Combio A/S, CelTor Inc., Torsana Biosensor)
- Fronted several successful exits over the last decade (NatImmune A/S to IPC, Combio A/S to Arpida AG, Torsana Biosensor A/S to Celtor Inc) as well as heading out-licensing, acquisitions, in-licensing etc.
|
|
|
|
 |
|
CSO
Kristian Helin, Ph.D.
- World leader in the field of oncology, epigenetics and histone modifying enzymes
- Founded EpiTherapeutics with members of his laboratory at Biotech Research & Innovation Centre (BRIC), University of Copenhagen
- Professor and Founding Director of BRIC, University of Copenhagen and Danish national Research Foundation’s Centre for Epigenetics
- More than 100 papers in high impact journals including Nature, Cell and Genes & Development
- Former divisional director of the European Institute of Oncology in Milan
|
|
|
|
 |
|
Vice President Chemistry
Marc Labelle, Ph.D.
- Chemistry leadership role in the discovery of two marketed products – Singulair™ (annual sales USD +4B) and CORDAPTIVE™ (projected annual sales USD 0.4B first year)
- VP Chemistry Lundbeck Research (2006 – 2009) and former VP at ImClone Systems, Director at Tularik/Amgen and Merck Frosst Canada Inc
- - 50 peer reviewed publications and 31 patent families published
|
|
|
|
 |
|
Vice President Biology
Peter Birk, Ph.D.
- CSO of ACE Bioscience A/S (until August 2009)
- VP in Pharmexa A/S (2004 – 2008)
- Various project managing and scientific positions in Pharmexa A/S, Statens Serum Institute and Odense University (1993 – 2004)
|
|
|
|
 |
|
Business Development Director
Henrik Blou, M.Sc.
- Founder, CEO/COO of MycoTeQ A/S (2006 – 2009)
- Management consultant with McKinsey & Company (2004 – 2006) focusing on operations management, M&A and procurement in the pharma industry
- Consultant to Aros Pharma and EpiTherapeutics prior to joining Epitherapeutics as BD Director
|
|
|
|
|
|
|
